Table of Contents

2019-2024 Global Darbepoetin Alfa Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Darbepoetin Alfa Consumption 2014-2024
  • 2.1.2 Darbepoetin Alfa Consumption CAGR by Region
• 2.2 Darbepoetin Alfa Segment by Type
  • 2.2.1 Epogen
  • 2.2.2 Procrit
  • 2.2.3 Aranesp
  • 2.2.4 Others
• 2.3 Darbepoetin Alfa Consumption by Type
  • 2.3.1 Global Darbepoetin Alfa Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Darbepoetin Alfa Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Darbepoetin Alfa Sale Price by Type (2014-2019)
• 2.4 Darbepoetin Alfa Segment by Application
  • 2.4.1 Patients with Chronic Kidney Disease
  • 2.4.2 Patients with Cancer
  • 2.4.3 Others
• 2.5 Darbepoetin Alfa Consumption by Application
  • 2.5.1 Global Darbepoetin Alfa Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Darbepoetin Alfa Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Darbepoetin Alfa Sale Price by Application (2014-2019)

3 Global Darbepoetin Alfa by Players

• 3.1 Global Darbepoetin Alfa Sales Market Share by Players
  • 3.1.1 Global Darbepoetin Alfa Sales by Players (2017-2019)
  • 3.1.2 Global Darbepoetin Alfa Sales Market Share by Players (2017-2019)
• 3.2 Global Darbepoetin Alfa Revenue Market Share by Players
  • 3.2.1 Global Darbepoetin Alfa Revenue by Players (2017-2019)
  • 3.2.2 Global Darbepoetin Alfa Revenue Market Share by Players (2017-2019)
• 3.3 Global Darbepoetin Alfa Sale Price by Players
• 3.4 Global Darbepoetin Alfa Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Darbepoetin Alfa Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Darbepoetin Alfa Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Darbepoetin Alfa by Regions

• 4.1 Darbepoetin Alfa by Regions
  • 4.1.1 Global Darbepoetin Alfa Consumption by Regions
  • 4.1.2 Global Darbepoetin Alfa Value by Regions
• 4.2 Americas Darbepoetin Alfa Consumption Growth
• 4.3 APAC Darbepoetin Alfa Consumption Growth
• 4.4 Europe Darbepoetin Alfa Consumption Growth
• 4.5 Middle East & Africa Darbepoetin Alfa Consumption Growth

5 Americas

• 5.1 Americas Darbepoetin Alfa Consumption by Countries
  • 5.1.1 Americas Darbepoetin Alfa Consumption by Countries (2014-2019)
  • 5.1.2 Americas Darbepoetin Alfa Value by Countries (2014-2019)
• 5.2 Americas Darbepoetin Alfa Consumption by Type
• 5.3 Americas Darbepoetin Alfa Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Darbepoetin Alfa Consumption by Countries
  • 6.1.1 APAC Darbepoetin Alfa Consumption by Countries (2014-2019)
  • 6.1.2 APAC Darbepoetin Alfa Value by Countries (2014-2019)
• 6.2 APAC Darbepoetin Alfa Consumption by Type
• 6.3 APAC Darbepoetin Alfa Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Darbepoetin Alfa by Countries
  • 7.1.1 Europe Darbepoetin Alfa Consumption by Countries (2014-2019)
  • 7.1.2 Europe Darbepoetin Alfa Value by Countries (2014-2019)
• 7.2 Europe Darbepoetin Alfa Consumption by Type
• 7.3 Europe Darbepoetin Alfa Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Darbepoetin Alfa by Countries
  • 8.1.1 Middle East & Africa Darbepoetin Alfa Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Darbepoetin Alfa Value by Countries (2014-2019)
• 8.2 Middle East & Africa Darbepoetin Alfa Consumption by Type
• 8.3 Middle East & Africa Darbepoetin Alfa Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Darbepoetin Alfa Distributors
• 10.3 Darbepoetin Alfa Customer

11 Global Darbepoetin Alfa Market Forecast

• 11.1 Global Darbepoetin Alfa Consumption Forecast (2019-2024)
• 11.2 Global Darbepoetin Alfa Forecast by Regions
  • 11.2.1 Global Darbepoetin Alfa Forecast by Regions (2019-2024)
  • 11.2.2 Global Darbepoetin Alfa Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Darbepoetin Alfa Forecast by Type
• 11.8 Global Darbepoetin Alfa Forecast by Application

12 Key Players Analysis

• 12.1 Amgen
  • 12.1.1 Company Details
  • 12.1.2 Darbepoetin Alfa Product Offered
  • 12.1.3 Amgen Darbepoetin Alfa Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Amgen News
• 12.2 Johnson & Johnson
  • 12.2.1 Company Details
  • 12.2.2 Darbepoetin Alfa Product Offered
  • 12.2.3 Johnson & Johnson Darbepoetin Alfa Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Johnson & Johnson News
• 12.3 Kyowa Hakko Kirin
  • 12.3.1 Company Details
  • 12.3.2 Darbepoetin Alfa Product Offered
  • 12.3.3 Kyowa Hakko Kirin Darbepoetin Alfa Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Kyowa Hakko Kirin News
• 12.4 Novartis
  • 12.4.1 Company Details
  • 12.4.2 Darbepoetin Alfa Product Offered
  • 12.4.3 Novartis Darbepoetin Alfa Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Novartis News
• 12.5 3SBio
  • 12.5.1 Company Details
  • 12.5.2 Darbepoetin Alfa Product Offered
  • 12.5.3 3SBio Darbepoetin Alfa Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 3SBio News

...

13 Research Findings and Conclusion

Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.
Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.
North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.

According to this study, over the next five years the Darbepoetin Alfa market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Darbepoetin Alfa business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Darbepoetin Alfa market by product type, application, key manufacturers and key regions and countries.

This study considers the Darbepoetin Alfa value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Epogen
Procrit
Aranesp
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Patients with Chronic Kidney Disease
Patients with Cancer
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Amgen 
Johnson & Johnson
Kyowa Hakko Kirin
Novartis
3SBio
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Darbepoetin Alfa consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Darbepoetin Alfa market by identifying its various subsegments.
Focuses on the key global Darbepoetin Alfa manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Darbepoetin Alfa with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Darbepoetin Alfa submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.